Compare Heron Therapeutics Inc (HRTX) vs Consumer Staples Select Sector SPDR Fund (XLP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs Consumer Staples Select Sector SPDR Fund — how do they compare? Heron Therapeutics Inc trades at $0.37 (market cap $68.01M), while Consumer Staples Select Sector SPDR Fund trades at $83.05 (market cap $13.50B). The key difference: Consumer Staples Select Sector SPDR Fund is far larger — about 198.5× Heron Therapeutics Inc's market cap, and Consumer Staples Select Sector SPDR Fund is trading nearer its 52-week high, Heron Therapeutics Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Heron Therapeutics Inc for 35 Days and Consumer Staples Select Sector SPDR Fund for 72 Days on average.
| HRTX | XLP | |
|---|---|---|
Market Cap | $68.01M | $13.50B |
Volume | 1,891,941 | 14,599,953 |
Sector | Health | — |
52-Week High | $1.49 | $90.00 |
52-Week Low | $0.27 | $75.61 |
Typical Hold Time | 35 Days | 72 Days |
Enterprise Value | $174.75M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HRTX trades at $0.39, up 17.58% today, with a bullish technical signal from moving averages. The company reported Q2 2026 revenue of $37.7 million but missed EPS estimates with a $0.03 loss. Despite negative profitability metrics, analyst consensus remains strongly positive with 89% buy ratings. Recent news highlights ongoing comparisons with peers and earnings performance discussions.
The outlook is mixed: strong analyst support and technical momentum suggest potential upside, but persistent losses and high valuation ratios pose significant risks. Investment opportunity hinges on revenue growth translating to profitability, while key risks include execution challenges and competitive pressures in the biotechnology sector.
XLP trades at $81.70, showing slight weakness with a 0.09% decline amid bearish technical signals. The ETF maintains strong analyst support with a 100% buy rating from 2 analysts, though technical indicators show moving averages and overall signals are bearish. Recent news highlights XLP's defensive characteristics and competitive expense ratio advantage over peers.
The consumer staples ETF offers defensive exposure during market volatility, supported by positive sector performance in 2026. Key risks include interest rate sensitivity and potential consumer spending slowdowns. Analyst consensus remains bullish despite technical headwinds, positioning XLP as a core defensive holding.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About Consumer Staples Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes companies that have been identified as Consumer Staples companies by the GICS®. It is non-diversified.
Read more on XLP →
